DDInter1607 DDInter1615
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration. Neurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR). By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and late-phase CINV during the first 120 hours post-chemotherapy.
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rolapitant
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Dextromethorphan
Dextromethorphan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Ritonavir {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rolapitant
Ritonavir {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Iloperidone
Iloperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Enzalutamide {u} may lead to a major life threatening interaction when taken with {v} Rolapitant
Ritonavir {u} (Compound) causes {v} (Side Effect) Visual impairment
Visual impairment {u} (Side Effect) is caused by {v} (Compound) Primidone
Primidone {u} may lead to a major life threatening interaction when taken with {v} Rolapitant
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Naloxegol
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rolapitant
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Larotrectinib
Larotrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Nintedanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Paclitaxel
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Ritonavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Ritonavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Dextromethorphan (Compound) and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Ritonavir (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Ritonavir (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Iloperidone (Compound) and Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Ritonavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Rolapitant
Ritonavir (Compound) causes Visual impairment (Side Effect) and Visual impairment (Side Effect) is caused by Primidone (Compound) and Primidone may lead to a major life threatening interaction when taken with Rolapitant
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant